| Date | Time | Source | Headline | Symbol | Company |
| 09/18/2023 | 9:59AM | Dow Jones News | AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study | NYSE:ABBV | AbbVie Inc |
| 09/18/2023 | 9:00AM | PR Newswire (US) | Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence | NYSE:ABBV | AbbVie Inc |
| 09/14/2023 | 1:01PM | Dow Jones News | AbbVie Currently Up Six Consecutive Days, On Track for Longest Winning Streak Since March 2022 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 09/13/2023 | 5:12PM | Dow Jones News | Harpoon Shares Drop 7.3% as AbbVie Declines License Option | NYSE:ABBV | AbbVie Inc |
| 09/13/2023 | 4:55PM | Dow Jones News | Harpoon Therapeutics Says AbbVie Declines to Exercise License Option | NYSE:ABBV | AbbVie Inc |
| 09/13/2023 | 11:00AM | PR Newswire (US) | AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students" | NYSE:ABBV | AbbVie Inc |
| 09/12/2023 | 8:30AM | PR Newswire (US) | AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease | NYSE:ABBV | AbbVie Inc |
| 09/08/2023 | 11:23AM | PR Newswire (US) | AbbVie Declares Quarterly Dividend | NYSE:ABBV | AbbVie Inc |
| 09/07/2023 | 7:00AM | GlobeNewswire Inc. | Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease | NYSE:ABBV | AbbVie Inc |
| 09/06/2023 | 8:45AM | PR Newswire (US) | Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs | NYSE:ABBV | AbbVie Inc |
| 09/06/2023 | 8:00AM | PR Newswire (US) | AbbVie to Present at the Morgan Stanley Healthcare Conference | NYSE:ABBV | AbbVie Inc |
| 08/30/2023 | 9:00AM | PR Newswire (US) | Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic) | NYSE:ABBV | AbbVie Inc |
| 08/28/2023 | 9:50AM | Dow Jones News | AbbVie Seeks U.S., Europe OK for Skyrizi in Ulcerative Colitis | NYSE:ABBV | AbbVie Inc |
| 08/28/2023 | 8:45AM | PR Newswire (US) | AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis | NYSE:ABBV | AbbVie Inc |
| 08/24/2023 | 6:30AM | Finscreener.org | SCHD: Should You Buy the Schwab US Dividend Equity ETF for Its Dividend Yield? | NYSE:ABBV | AbbVie Inc |
| 08/17/2023 | 2:00AM | PR Newswire (US) | AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults | NYSE:ABBV | AbbVie Inc |
| 08/07/2023 | 1:10PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NYSE:ABBV | AbbVie Inc |
| 08/01/2023 | 8:45AM | PR Newswire (US) | Allergan Aesthetics Announces First Ever JUVÉDERM® Day | NYSE:ABBV | AbbVie Inc |
| 07/27/2023 | 10:36AM | Dow Jones News | AbbVie Up Over 6%, on Pace for Largest Percent Increase Since November 2020 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 07/27/2023 | 7:45AM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:ABBV | AbbVie Inc |
| 07/27/2023 | 7:38AM | PR Newswire (US) | AbbVie Reports Second-Quarter 2023 Financial Results | NYSE:ABBV | AbbVie Inc |
| 07/27/2023 | 7:25AM | IH Market News | Thursday’s Wall Street Highlights: Salesforce, Mattel, Shell, Meta, McDonald’s, and more | NYSE:ABBV | AbbVie Inc |
| 07/26/2023 | 9:00AM | PR Newswire (US) | AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets | NYSE:ABBV | AbbVie Inc |
| 07/26/2023 | 8:05AM | PR Newswire (US) | SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study | NYSE:ABBV | AbbVie Inc |
| 07/25/2023 | 4:30PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:ABBV | AbbVie Inc |
| 07/25/2023 | 7:55AM | Dow Jones News | AbbVie's Rinvoq Drug Gets Health Canada Green Light | NYSE:ABBV | AbbVie Inc |
| 07/25/2023 | 7:00AM | PR Newswire (Canada) | AbbVie reçoit l'approbation de Santé Canada pour l'emploi de RINVOQ® (upadacitinib) dans le traitement des adultes atteints de colite ulcéreuse modérément à fortement évolutive | NYSE:ABBV | AbbVie Inc |
| 07/25/2023 | 7:00AM | PR Newswire (Canada) | Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis | NYSE:ABBV | AbbVie Inc |
| 07/24/2023 | 8:05AM | PR Newswire (US) | AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa | NYSE:ABBV | AbbVie Inc |
| 07/21/2023 | 4:30AM | PR Newswire (US) | AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NYSE:ABBV | AbbVie Inc |